PHARMALA BIOTECH HLDG INC - $MDXXF STOCK NEWS

Welcome to our dedicated page for PHARMALA BIOTECH HLDG news (Ticker: $MDXXF), a resource for investors and traders seeking the latest updates and insights on PHARMALA BIOTECH HLDG stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PHARMALA BIOTECH HLDG's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PHARMALA BIOTECH HLDG's position in the market.

04/05/2024 08:58 AM

News

Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia

Rhea-AI Summary

PharmAla Biotech Holdings Inc. announces the commencement of batch manufacturing of GMP LaNeo® MDMA 40mg capsules by its joint venture, Cortexa Pty. , marking a significant milestone in the Australian psychedelic landscape. The exclusive arrangement with Optima Ovest for domestic manufacturing strengthens Cortexa's position as a leader in the field and signals commitment to the growing Australian market for LaNeo™ MDMA.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-5.55%

Tags

03/27/2024 08:00 AM

News

Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office

Rhea-AI Summary

PharmAla Biotech Holdings Inc. receives USPTO allowance for ALA-002 patent, a novel mixture of MDMA enantiomers with improved therapeutic potential. The patent provides strong IP protection for the company's lead investigational MDXX NCE, showing reduced hyperthermia incidence and enhanced pro-social effects in preclinical testing.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.85%

Tags

03/20/2024 10:20 AM

News

Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office

Rhea-AI Summary

PharmAla Biotech Holdings Inc. has received a patent for its PharmAla-1 molecule, now known as APA-001, which shows promising therapeutic features in proof-of-concept rodent models. The molecule has a strong pro-social signal, induces neuroplasticity, and has a low abuse liability. The company is evaluating potential applications in treating psychological trauma, neurological damage, Traumatic Brain Injury (TBI), stroke, and fear disorders.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

2.13%

Tags

03/18/2024 08:55 AM

News

Cortexa Leads the World in First Supply of Psilocybin Under the TGA’s Authorized Prescriber Scheme

Rhea-AI Summary

PharmAla becomes the first company to supply both MDMA and Psilocybin into the Australian Market, establishing a significant presence in the psychedelic medicine sector.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

03/08/2024 08:05 AM

News

Red Light Holland Commences Experimental Research on Psilocybin Truffles to Develop Process for Commercial Manufacturing of Natural-Source Active Pharmaceutical Ingredient

Rhea-AI Summary

Red Light Holland Corp. initiates a research project to develop a process for manufacturing natural-source Active Pharmaceutical Ingredient (API) derived from psilocybin truffles. The project aims to produce high-margin Psilocybin medical products and gain valuable intellectual property. Researchers from PharmAla Biotech will manage the project, focusing on extraction and purification of Psilocybin for use in various markets.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

6.42%

Tags

01/24/2024 09:35 AM

News

PharmAla receives new “MDXXF” ticker from FINRA for OTCQB Listing

Rhea-AI Summary

PharmAla Biotech Holdings Inc. announced the immediate change of its OTC ticker symbol to 'MDXXF' to better align with its focus on the research, development, and manufacturing of MDXX class molecules. The company's CEO, Nick Kadysh, expressed excitement for the attention it will receive from US audiences as the FDA is set to announce its assessment approach for MDMA as a therapeutic molecule. PharmAla will release its Q1 financial statements on January 29th, 2024.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags